-
MPP7, EMT, and Polarity in Ovarian Cancer
2026-09-15
The reference study links elevated MPP7 with poor prognosis and shows that MPP7 interference suppresses epithelial ovarian cancer cell growth, migration, and invasion while altering planar polarity. Its integrated use of database analysis, tissue immunohistochemistry, functional assays, transcriptomics, and Western blotting supports a model in which MPP7 may promote EMT through Wnt/β-catenin signaling.
-
AMD-070 Hydrochloride: Receptor Biology in WHIM
2026-09-15
AMD-070 hydrochloride is an oral CXCR4 antagonist whose value extends beyond receptor inhibition to disease-relevant modeling of WHIM syndrome. This article connects CXCR4 receptor-state biology, phase 3 evidence, assay design, and carefully bounded anti-HIV research applications.
-
SGI-1027 and Everolimus in Renal Cancer
2026-09-14
A 2024 Advanced Science study identifies SGI-1027 as a methuosis-inducing agent and shows that it cooperates with everolimus to restrict renal cancer growth, migration, and invasion. The combination links lysosomal membrane permeability with apoptosis and GSDME-dependent pyroptosis, providing a preclinical strategy for addressing limitations of everolimus-based therapy.
-
RBMS1 Loss Enables PD-L1 Blockade in TNBC
2026-09-14
The reference study identifies the RNA-binding protein RBMS1 as a post-transcriptional regulator of PD-L1 stability in immune-cold triple-negative breast cancer. Its experiments connect RBMS1 depletion to B4GALT1 mRNA destabilization, impaired PD-L1 glycosylation, enhanced PD-L1 degradation, and stronger responses to T-cell-based treatment strategies.
-
Adefovir Dipivoxil in Chronic Hepatitis B
2026-09-13
Hadziyannis and Papatheodoridis established a clinically focused framework for understanding adefovir dipivoxil as a nucleotide analog therapy for chronic hepatitis B, integrating its activation, HBV DNA polymerase inhibition, efficacy, resistance profile, and safety. The review remains useful for designing hepatitis B virus research workflows because it connects molecular chain termination with outcomes across HBeAg-positive, HBeAg-negative, and lamivudine-resistant disease.
-
Benzyl-activated Streptavidin Magnetic Beads
2026-09-12
Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) provide magnetically assisted capture of biotinylated proteins, peptides, antibodies, oligonucleotides, and other molecules from complex samples. They are appropriate for affinity purification, immunoprecipitation, interaction assays, and screening workflows, but require validation when samples contain azide-sensitive systems, non-biotinylated targets, or conditions outside the supplied buffer environment.
-
UPRER Activation and Cadmium Resistance in C. elegans
2026-09-12
The reference study shows that mild activation of the endoplasmic reticulum unfolded protein response can improve cadmium resistance in Caenorhabditis elegans by preserving protein homeostasis. Its genetic evidence identifies the IRE-1/XBP-1 branch and DAF-16/FOXO as important components, while demonstrating that excessive UPRER activation can become harmful.
-
WEHI-539: Selective BCL-XL Inhibitor Guide
2026-09-11
WEHI-539 is a selective BCL-XL inhibitor that engages the BH3-binding groove and promotes mitochondrial apoptosis in BCL-XL-dependent models. Its subnanomolar biochemical potency supports apoptosis research, while BAK dependence, formulation limits, and preclinical status define appropriate use.
-
From Fluorescent mRNA to Spatiotemporal Delivery
2026-09-11
A translational framework for using dual-readout fluorescent mRNA to connect intracellular delivery, translation, and immune-relevant targeting decisions.
-
D-N-Acetylgalactosamine: Practical Protocol Guide
2026-09-10
D-N-Acetylgalactosamine (SKU B7904) provides a defined, water-soluble carbohydrate-related reagent for controlled glycoprotein and brain heteropolysaccharide workflows. It is suitable for freshly prepared aqueous or DMSO solutions, but not for ethanol-based procedures or long-term storage of prepared solutions.
-
Adefovir: From Polymerase Readout to OAT1
2026-09-10
Adefovir (GS-0393) is more than an HBV polymerase inhibitor: it connects antiviral pharmacology with renal OAT1 transport biology. This article explains how to design assays that distinguish molecular potency, cellular exposure, and transporter-mediated clearance.
-
NLRP3 Astrocyte Remodeling in Morphine Tolerance
2026-09-09
Yuan et al. link spinal NLRP3 inflammasome activation with a shift toward the neurotoxic A1 astrocyte phenotype during morphine tolerance. Their MCC950 intervention study suggests that inflammasome inhibition can slow tolerance development while normalizing inflammatory and astrocyte-state markers, although the findings remain mechanistic and preclinical.
-
OMV-Displayed mRNA Antigens for Tumor Vaccines
2026-09-09
The reference study developed genetically engineered bacterial outer membrane vesicles that rapidly capture sequence-labeled mRNA antigens and promote their delivery, endosomal escape, and cross-presentation in dendritic cells. This plug-and-display system produced antitumor activity and immune memory in mouse models, while also highlighting manufacturing and translational questions for personalized mRNA vaccination.
-
Protease Inhibitor Cocktail for DFCP1–ATGL Assays
2026-09-08
A practical workflow for preserving DFCP1, ATGL, and lipid-droplet complexes during starvation and extraction studies. Learn how to use an EDTA-containing Protease Inhibitor Cocktail for Western blotting, Co-IP, tissue lysates, imaging support, and kinase assays while avoiding chelation-related artifacts.
-
Mavorixafor Hydrochloride: Assay Strategy
2026-09-08
AMD-070 hydrochloride is more than a CXCR4 antagonist: it enables genotype-aware studies of migration, signaling, and disease-context biology. This guide connects WM-focused evidence with practical assays, handling decisions, and carefully bounded anti-HIV research applications.